Key Points
- CFO Kamran Alam sold 23,849 shares on Jan. 26 at $4.61 for about $109,944 and now owns 1,443,786 shares, a 1.62% reduction in his stake.
- Multiple insiders — the CFO, CEO Sean P. Nolan, and director Sukumar Nagendran — sold a combined ≈396,968 shares on Jan. 23 and Jan. 26 for roughly $1.87 million, materially reducing their ownership percentages.
- Taysha (TSHA) trades near $4.76 (52‑week range $1.05–$6.02) with a market cap around $1.3B and negative earnings metrics, yet analysts carry a Moderate Buy consensus and a ~$10.67 average price target.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) CFO Kamran Alam sold 23,849 shares of the firm's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the transaction, the chief financial officer owned 1,443,786 shares in the company, valued at $6,655,853.46. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Kamran Alam also recently made the following trade(s):
- On Friday, January 23rd, Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00.
Taysha Gene Therapies Stock Up 0.8%
TSHA stock opened at $4.76 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a 50-day moving average of $5.09 and a two-hundred day moving average of $4.08. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on TSHA shares. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, January 5th. Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Robert W. Baird boosted their price objective on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an "outperform" rating in a report on Thursday, October 2nd. JMP Securities set a $8.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Citizens Jmp boosted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "market outperform" rating in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $10.67.
Read Our Latest Stock Report on TSHA
Institutional Trading of Taysha Gene Therapies
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. B Group Inc. boosted its stake in Taysha Gene Therapies by 43.4% in the 2nd quarter. B Group Inc. now owns 1,800,556 shares of the company's stock valued at $4,159,000 after buying an additional 545,000 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at $1,890,000. Affinity Asset Advisors LLC bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth about $462,000. Jefferies Financial Group Inc. increased its position in shares of Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock worth $23,825,000 after purchasing an additional 10,068,479 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Taysha Gene Therapies during the 2nd quarter valued at about $186,000. Institutional investors own 77.70% of the company's stock.
Key Headlines Impacting Taysha Gene Therapies
Here are the key news stories impacting Taysha Gene Therapies this week:
- Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
- Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
- Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
